{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:05:22Z","timestamp":1791227122640,"version":"4.1.0"},"reference-count":35,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T00:00:00Z","timestamp":1547251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T00:00:00Z","timestamp":1547251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Beijing Science and Technology Commission, Study on the clinical characteristics of the Capital, \u201cSpecial financing topics,\u201d","award":["Z151100004015044"],"award-info":[{"award-number":["Z151100004015044"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1111\/jcpt.12792","type":"journal-article","created":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T17:54:06Z","timestamp":1547315646000},"page":"300-311","source":"Crossref","is-referenced-by-count":17,"title":["Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy"],"prefix":"10.1155","volume":"44","author":[{"given":"Chao-Yang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Peking University First Hospital; Beijing China"},{"name":"School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Peking University First Hospital; Beijing China"},{"name":"School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Peking University First Hospital; Beijing China"},{"name":"School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2019,1,12]]},"reference":[{"key":"10.1111\/jcpt.12792-BIB0001|jcpt12792-cit-0001","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/bcp.13392","article-title":"Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children","volume":"83","author":"Rodrigues","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12792-BIB0002|jcpt12792-cit-0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","article-title":"Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy","volume":"35","author":"Park","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/jcpt.12792-BIB0003|jcpt12792-cit-0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12792-BIB0004|jcpt12792-cit-0004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydrocarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12792-BIB0005|jcpt12792-cit-0005","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.109.030593","article-title":"Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine","volume":"39","author":"Flesch","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12792-BIB0006|jcpt12792-cit-0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ftd.0000155342.93489.fd","article-title":"10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs","volume":"27","author":"Armijo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12792-BIB0007|jcpt12792-cit-0007","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/bjp.2008.366","article-title":"Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain","volume":"155","author":"Clinckers","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jcpt.12792-BIB0008|jcpt12792-cit-0008","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"10.1111\/jcpt.12792-BIB0009|jcpt12792-cit-0009","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ejps.2017.05.034","article-title":"Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects","volume":"109S","author":"Antunes","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1111\/jcpt.12792-BIB0010|jcpt12792-cit-0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine","volume":"24","author":"Flesch","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1111\/jcpt.12792-BIB0011|jcpt12792-cit-0011","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions - principles and clinical implications","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"10.1111\/jcpt.12792-BIB0012|jcpt12792-cit-0012","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/aps.2014.76","article-title":"Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1111\/jcpt.12792-BIB0013|jcpt12792-cit-0013","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","article-title":"Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities","volume":"30","author":"Sugiyama","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12792-BIB0014|jcpt12792-cit-0014","first-page":"668","article-title":"Evaluation of the population pharmacokinetic models of oxcarbazepine in pediatric patients with epilepsy","volume":"25","author":"Li","year":"2016","journal-title":"Chin J New Drugs"},{"key":"10.1111\/jcpt.12792-BIB0015|jcpt12792-cit-0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/FTD.0000000000000278","article-title":"Saliva and plasma monohydroxycarbamazepine concentrations in pediatric patients with epilepsy","volume":"38","author":"Li","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12792-BIB0016|jcpt12792-cit-0016","volume-title":"NONMEM User's Guide, Part I-VII","author":"Beal","year":"1988"},{"key":"10.1111\/jcpt.12792-BIB0017|jcpt12792-cit-0017","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1111\/jcpt.12792-BIB0018|jcpt12792-cit-0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using nonmem","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1111\/jcpt.12792-BIB0019|jcpt12792-cit-0019","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazepine in man","volume":"16","author":"Sch\u00fctz","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1111\/jcpt.12792-BIB0020|jcpt12792-cit-0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","article-title":"Pharmacokinetic drug interactions in children taking oxcarbazepine","volume":"74","author":"Sallas","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12792-BIB0021|jcpt12792-cit-0021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.2015.1019463","article-title":"Prediction of drug clearance in children: a review of different methodologies","volume":"11","author":"Mahmood","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/jcpt.12792-BIB0022|jcpt12792-cit-0022","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/17425255.2014.872630","article-title":"Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs","volume":"10","author":"Piana","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/jcpt.12792-BIB0023|jcpt12792-cit-0023","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s13318-015-0266-5","article-title":"Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy","volume":"41","author":"Yu","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12792-BIB0024|jcpt12792-cit-0024","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5414\/CP202078","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy","volume":"52","author":"Peng","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12792-BIB0025|jcpt12792-cit-0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/jcpt.12792-BIB0026|jcpt12792-cit-0026","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s11095-012-0668-x","article-title":"A bodyweight-dependent allometric exponent for scaling clearance across the human life-span","volume":"29","author":"Wang","year":"2012","journal-title":"Pharm Res"},{"key":"10.1111\/jcpt.12792-BIB0027|jcpt12792-cit-0027","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2125.1993.tb00378.x","article-title":"The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid","volume":"36","author":"Tartara","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12792-BIB0028|jcpt12792-cit-0028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.1994.tb04234.x","article-title":"A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients","volume":"37","author":"McKee","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12792-BIB0029|jcpt12792-cit-0029","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12792-BIB0030|jcpt12792-cit-0030","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","article-title":"Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy","volume":"51","author":"Wegner","year":"2010","journal-title":"Epilepsia"},{"key":"10.1111\/jcpt.12792-BIB0031|jcpt12792-cit-0031","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.0013-9580.2003.06203.x","article-title":"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate","volume":"44","author":"Nallani","year":"2003","journal-title":"Epilepsia"},{"key":"10.1111\/jcpt.12792-BIB0032|jcpt12792-cit-0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00194967","article-title":"The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites","volume":"47","author":"Rouan","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12792-BIB0033|jcpt12792-cit-0033","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/bdd.716","article-title":"Binding of licarbazepine enantiomers to mouse and human plasma proteins","volume":"31","author":"Fortuna","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1111\/jcpt.12792-BIB0034|jcpt12792-cit-0034","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy","volume":"69","author":"Striano","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1111\/jcpt.12792-BIB0035|jcpt12792-cit-0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.seizure.2015.07.018","article-title":"Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy","volume":"31","author":"Sattler","year":"2015","journal-title":"Seizure"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12792\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:59:13Z","timestamp":1694555953000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,12]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12792","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,12]]}}}